Conversion of sugar to fat: Is hepatic de novo lipogenesis leading to metabolic syndrome and associated chronic diseases?

Journal of the American Osteopathic Association

Volumn 117, Issue 8, 2017, Pages 520-527

  Schwarz, Jean Marc ^a,b   Clearfield, Michael ^a   Mulligan, Kathleen ^a,b  

^a Touro University California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

De novo lipogenesis; Fatty liver disease; Metabolic syndrome

Indexed keywords

CHRONIC DISEASE; DIET; FATTY LIVER; HUMAN; LIPOGENESIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; SUGAR INTAKE;

CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DIET; DIETARY SUGARS; FATTY LIVER; HUMANS; LIPOGENESIS; METABOLIC SYNDROME;

EID: 85026655560     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: 10.7556/jaoa.2017.102     Document Type: Review

References (45)

1. Guideline: Sugars Intake for Adults and Children. Geneva, Switzerland: World Health Organization; 2015.
2. Johnson RK, Appel LJ, Brands M, et al; American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism and the Council on Epidemiology and Prevention. Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2009;120(11):1011-1020. doi:10.1161/CIRCULATIONAHA.109.192627
3. 2015-2020 Dietary Guidlines for Americans. 8th ed. Washington, DC: US Dept of Health and Human Services, US Dept of Agriculture; 2015.
4. Gerteis J, Izrael D, Deitz D, et al. Multiple Chronic Conditions Chartbook: 2010 Medical Expenditure Panel Survey Data. Washington, DC: Dept of Health and Human Services, Agency for Healthcare Research and Quality; 2014.
5. Mensah G. Global and Domestic Health Priorities: Spotlight on Chronic Disease. National Business Group on Health Webinar. May 23, 2006.
6. Sanders TA. How important is the relative balance of fat and carbohydrate as sources of energy in relation to health? Proc Nutr Soc. 2016;75(2):147-153. doi:10.1017/S0029665115004188
7. Nestle M. Conflicts of interest in the regulation of food safety: a threat to scientific integrity. JAMA Intern Med. 2013;173(22):2036-2038. doi:10.1001/jamainternmed.2013.9158
8. Kearns CE, Schmidt LA, Glantz SA. Sugar industry and coronary heart disease research: a historical analysis of iInternal industry documents. JAMA Intern Med. 2016;176(11):1680-1685. doi:10.1001/jamainternmed.2016.5394
9. Hellerstein MK, Schwarz JM, Neese RA. Regulation of hepatic de novo lipogenesis in humans. Ann Rev Nutr. 1996;16:523-557. doi:10.1146/annurev.nu.16.070196.002515
10. Faeh D, Minehira K, Schwarz J-M, et al. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes. 2005;54(7):1907-1913.
11. Stanhope K, Schwarz J-M, Keim N, et al. Consuming fructose-sweetened, not glucose-sweetened beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119(5):1322-1334. doi:10.1172/JCI37385
12. Schwarz J-M, Noworolski SM, Wen MJ, et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. J Clin Endocrinol Metab. 2015;100(6):2434-2442. doi:10.1210/jc.2014-3678.
13. Schwarz J-M, Noworolski SM, Erkin-Cakmak A, et al. Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity [published online ahead of print June 1, 2017]. Gastroenterology. doi:10.1053/j.gastro.2017.05.043
14. Mayes PA. Intermediary metabolism of fructose. Am J Clin Nutr. 1993;58(5 Suppl):754S-765S.
15. Hudgins LC, Parker TS, Levine DM, Hellerstein MK. A dual sugar challenge test for lipogenic sensitivity to dietary fructose. J Clin Endocrinol Metab. 2011;96(3):861-868.
16. Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity [published correction appears in Am J Clin Nutr. 2004;80(4):1090]. Am J Clin Nutr. 2004;79(4):537-543.
17. Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: a systematic review. Am J Clin Nutr. 2006;84(2):274-288.
18. Xi B, Huang Y, Reilly KH, et al. Sugar-sweetened beverages and risk of hypertension and CVD: a dose-response meta-analysis. Br J Nutr. 2015;113(5):709-717. doi:10.1017/S0007114514004383
19. Richelsen B. Sugar-sweetened beverages and cardio-metabolic disease risks. Curr Opin Clin Nutr Metab Care. 2013;16(4):478-484. doi:10.1097/MCO.0b013e328361c53e
20. Jin R, Vos MB. Fructose and liver function–is this behind nonalcoholic liver disease? Curr Opin Clin Nutr Metab Care. 2015;18(5):490-495. doi:10.1097/MCO.0000000000000203
21. Corn Refiners Applaud American Medical Association Decision on High Fructose Corn Syrup [press release]. Chicago, IL: American Medical Association; June 19, 2008. https://corn.org/ama-decision-onhfcs/. Accessed July 7, 2017.
22. Chiavaroli L, de Souza RJ, Ha V, et al. Effect of fructose on established lipid targets: a systematic review and meta-analysis of controlled feeding trials. J Am Heart Assoc. 2015;4(9):e001700. doi:10.1161/JAHA.114.001700
23. Hellerstein MK, Christiansen M, Kaempfer S, et al. Measurement of de novo hepatic lipogenesis in humans using stable isotopes. J Clin Invest. 1991;87(5):1841-1852. doi:10.1172/JCI115206
24. Herman MA, Samuel VT. The sweet path to metabolic demise: fructose and lipid synthesis. Trends Endocrinol Metab. 2016; 27 (10):719-730. doi:10.1016/j.tem.2016.06.005
25. Timlin MT, Parks EJ. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am J Clin Nutr. 2005;81 (1):35-42.
26. Schwarz J-M, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr. 2003;77(1):43-50.
27. Schwarz J-M, Neese RA, Turner S, Dare D, Hellerstein MK. Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and whole-body fuel selection. J Clin Invest. 1995;96 (6):2735-2743. doi:10.1172/JCI118342
28. Thorburn AW, Storlien LH, Jenkins AB, Khouri S, Kraegen EW. Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am J Clin Nutr. 1989;49(6):1155-1163.
29. Jurgens H, Haass W, Castaneda TR, et al. Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res. 2005;13(7):1146-1156. doi:10.1038/oby.2005.136
30. Parks EJ, Krauss RM, Christiansen MP, Neese RA, Hellerstein MK. Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J Clin Invest. 1999;104 (8):1087-1096. doi:10.1172/JCI6572
31. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001;96 (10):2957-2961. doi:10.1111/j.1572-0241.2001.04667.x
32. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42 (5):987-1000. doi:10.1002/hep.20920
33. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106(36):15430-15435. doi:10.1073/pnas.0904944106
34. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-1351. doi:10.1172/JCI23621
35. Schwarz J-M, Mulligan K, Lee J, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2002;87(2):942. doi:10.1210/jcem.87.2.8391
36. Schwarz JM, Chiolero R, Revelly JP, et al. Effects of enteral carbohydrates on de novo lipogenesis in critically ill patients. Am J Clin Nutr. 2000;72(4):940-945.
37. Minehira K, Tappy L, Chiolero R, et al. Fractional hepatic de novo lipogenesis in healthy subjects during near-continuous oral nutrition and bed rest: a comparison with published data in artificially fed, critically ill patients. Clin Nutr. 2002;21(4): 345-350.
38. Tappy L, Schwarz J-M, Schneiter P, et al. Effects of isoenergetic glucose-based or lipid-based parenteral nutrition on glucose metabolism, de novo lipogenesis, and respiratory gas exchanges in critically ill patients. Crit Care Med. 1998;26(5):860-867.
39. Tappy L, Berger M, Schwarz J-M, et al. Hepatic and peripheral glucose metabolism in intensive care patients receiving continuous high-or low-carbohydrate enteral nutrition. JPEN J Parenter Enteral Nutr. 1999;23(5):260-267. doi:10.1177/0148607199023005260
40. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell. 2000;6(1):77-86.
41. Lustig RH, Mulligan K, Noworolski SM, et al. Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. Obesity (Silver Spring). 2016;24(2):453-460.
42. Gugliucci A, Lustig RH, Caccavello R, et al. Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis. 2016;253:171-177. doi:10.1016/j.atherosclerosis.2016.06.048
43. Aaron DG, Siegel MB. Sponsorship of national health organizations by two major soda companies. Am J Prev Med. 2017;52(1):20-30. doi:10.1016/j.amepre.2016.08.010
44. List of health professionals and scientific experts. Coca-Cola Journey website. http://transparency.coca-colacompany.com/health-professionalsand-scientific-experts. Accessed June 5, 2017.
45. Still AT. Philosophy of osteopathy. OsteoLib. 1899;1a:28.